However, significant limitations exist in the current evidence: Most human data comes from small studies, with limited randomised controlled trials specifically designed to assess alcohol consumption The mechanisms by which GLP-1 medications might reduce alcohol intake are not fully understood Individual responses vary considerably, and not all patients experience changes in drinking behaviour Long-term effects and safety of using these medications specifically for alcohol reduction remain unknown The MHRA has not approved GLP-1 receptor agonists for alcohol use disorder, and these medications should not be considered a treatment for problematic drinking
Growth response to various GH constructs
Our dietitian-designed collection includes delicious, pre-portioned, calorie-conscious meals with a focus on lean protein, high-fiber foods to aid digestion and stabilize blood glucose
PLoS ONE 2019;14:e0214275
doi: 10.1684/ejd.2012.1884
The Journal of clinical investigation, 131(1), e140065